Canada is an attractive market for pharmaceutical manufacturers. While universal healthcare does not currently extend to drugs in an outpatient setting, most Canadian consumers have some form of drug coverage through...more
Update: On November 23, Innovative Medicines Canada and a number of pharmaceutical companies commenced an application for judicial review of the final Guidelines. See also the PMPRB’s November 20, 2020 webinar slides here....more
11/5/2020
/ Canada ,
Drug Pricing ,
Health Canada ,
Life Sciences ,
Patented Medicine Prices Review Board (PMPRB) ,
Patented Medicines ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Rebates ,
Vaccinations
Update: See our article here regarding the final October 2020 Guidelines. On November 23, Innovative Medicines Canada and a number of pharmaceutical companies commenced an application for judicial review of the final...more
On December 2, 2017 Canada’s Governor-in-Council published proposed Regulations Amending the Patented Medicines Regulations (“the proposed Regulations”). The 75-day consultation period ends February 15, 2018. The proposed...more
12/5/2017
/ Canada ,
Consultation Periods ,
Drug Pricing ,
Health Canada ,
Life Sciences ,
Patent Act ,
Patented Medicine Prices Review Board (PMPRB) ,
Patented Medicines ,
Pharmaceutical Industry ,
Proposed Regulation ,
Reporting Requirements ,
Third-Party
The following are highlights of developments in Canadian life sciences intellectual property and regulatory law in 2016, updating our 2016 mid-year highlights.
1. Substantive patent law developments -
Utility and...more
1/11/2017
/ Administrative Proceedings ,
Anti-Competitive ,
Apotex ,
Arbitration ,
AstraZeneca ,
Bayer ,
Biologics ,
Biosimilars ,
CADTH ,
Calculation of Damages ,
CETA ,
Competition Authorities ,
Constitutional Challenges ,
Data Protection ,
Double Patent ,
Eli Lilly ,
Generic Drugs ,
Health Canada ,
Leave to Appeal ,
Life Sciences ,
NAFTA ,
New Guidance ,
Obviousness ,
Patent Infringement ,
Patent Litigation ,
Patent Terms ,
Patented Medicine Prices Review Board (PMPRB) ,
Patents ,
Pfizer ,
Pharmaceutical Patents ,
PMNOC Regulations ,
Supreme Court of Canada ,
Teva Pharmaceuticals ,
Trans-Pacific Partnership ,
Unjust Enrichment ,
Utility Patents